4.5 Article

Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers

期刊

HUMAN MOLECULAR GENETICS
卷 19, 期 14, 页码 2886-2897

出版社

OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddq174

关键词

-

资金

  1. Cancer Research UK [C1287/A8874, C5047/A8385, 11022, 10118, C1287/A10118, 11174, A10123] Funding Source: Medline
  2. Intramural NIH HHS Funding Source: Medline
  3. NCI NIH HHS [R01 CA122340, R01 CA128978] Funding Source: Medline
  4. Cancer Research UK [11022, 10118, 19275, 11174] Funding Source: researchfish

向作者/读者索取更多资源

Recent studies have identified single nucleotide polymorphisms (SNPs) that significantly modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Since these risk modifiers were originally identified as genetic risk factors for breast cancer in genome-wide association studies (GWASs), additional risk modifiers for BRCA1 and BRCA2 may be identified from promising signals discovered in breast cancer GWAS. A total of 350 SNPs identified as candidate breast cancer risk factors (P < 1 x 10(-3)) in two breast cancer GWAS studies were genotyped in 3451 BRCA1 and 2006 BRCA2 mutation carriers from nine centers. Associations with breast cancer risk were assessed using Cox models weighted for penetrance. Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P-trend < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P-trend = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P-trend = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P-trend = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P-trend = 1.7 x 10(-4)). The magnitude and direction of the associations were consistent with the original GWAS. In subsequent risk assessment studies, the loci appeared to interact multiplicatively for breast cancer risk in BRCA1 and BRCA2 carriers. Promising candidate SNPs from GWAS were identified as modifiers of breast cancer risk in BRCA1 and BRCA2 carriers. Upon further validation, these SNPs together with other genetic and environmental factors may improve breast cancer risk assessment in these populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood

Kara N. Maxwell, Vishal Patel, Kevin T. Nead, Shana Merrill, Dana Clark, Qinqin Jiang, Bradley Wubbenhorst, Kurt D'Andrea, Roger B. Cohen, Susan M. Domchek, Jennifer J. D. Morrissette, Roger A. Greenberg, Daria Babushok, Katherine L. Nathanson

Summary: Inherited biallelic pathogenic variants (PVs) in BRCA2 can cause Fanconi Anemia complementation group D1 (FA-D1). Our study identified a case where the individual with biallelic BRCA2 PVs did not have bone marrow failure but developed multiple cancers. This expands the clinical spectrum of FA-D1 and emphasizes the importance of early recognition of this syndrome in families.

CLINICAL GENETICS (2023)

Article Biochemistry & Molecular Biology

Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men

Anqi Wang, Yili Xu, Yao Yu, Kevin T. Nead, TaeBeom Kim, Keren Xu, Tokhir Dadaev, Ed Saunders, Xin Sheng, Peggy Wan, Loreall Pooler, Lucy Y. Xia, Stephen Chanock, Sonja Berndt, Susan M. Gapstur, Victoria Stevens, Demetrius Albanes, Stephanie J. Weinstein, Vincent Gnanapragasam, Graham G. Giles, Tu Nguyen-Dumont, Roger L. Milne, Mark M. Pomerantz, Julie A. Schmidt, Konrad H. Stopsack, Lorelei A. Mucci, William J. Catalona, Kurt N. Hetrick, Kimberly F. Doheny, Robert J. MacInnis, Melissa C. Southey, Rosalind A. Eeles, Fredrik Wiklund, Zsofia Kote-Jarai, Adam J. de Smith, David Conti, Chad Huff, Christopher A. Haiman, Burcu F. Darst

Summary: This study found that clonal hematopoiesis of indeterminate potential (CHIP) was not significantly associated with the risk of prostate cancer. Although CHIP was weakly associated with genetic risk of overall prostate cancer, there was no significant association with genes related to aggressive prostate cancer.

HUMAN MOLECULAR GENETICS (2023)

Article Oncology

NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects

Sami Belhadj, Aliya Khurram, Chaitanya Bandlamudi, Guillermo Palou-Marquez, Vignesh Ravichandran, Zoe Steinsnyder, Temima Wildman, Amanda Catchings, Yelena Kemel, Semanti Mukherjee, Benjamin Fesko, Kanika Arora, Miika Mehine, Sita Dandiker, Aalin Izhar, John Petrini, Susan Domchek, Katherine L. Nathanson, Jamie Brower, Fergus Couch, Zsofia Stadler, Mark Robson, Michael Walsh, Joseph Vijai, Michael Berger, Fran Supek, Rachid Karam, Sabine Topka, Kenneth Offit

Summary: Through sequencing analysis of matched germline and somatic DNA samples from 34,046 patients, 32 pathogenic variants of NBN were identified. Patients carrying these variants showed increased loss of wild-type allele in lung and pancreatic tumors. Functional studies confirmed the important role of NBN in a broad spectrum of cancers.

CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

Gisella Figlioli, Amandine Billaud, Thomas U. Ahearn, Natalia N. Antonenkova, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Marinus J. Blok, Natalia Bogdanova, Bernardo Bonanni, Barbara Burwinkel, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Melissa H. Cessna, Stephen J. Chanock, Kamila Czene, Peter Devilee, Thilo Doerk, Christoph Engel, Mikael Eriksson, Peter A. Fasching, Jonine D. Figueroa, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Anna Gonzalez-Neira, Felix Grassmann, Pascal Guenel, Melanie Gundert, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Patricia A. Harrington, Wei He, Peter Hillemanns, Antoinette Hollestelle, Maartje J. Hooning, Reiner Hoppe, Anthony Howell, Keith Humphreys, Agnes Jager, Anna Jakubowska, Elza K. Khusnutdinova, Yon-Dschun Ko, Vessela N. Kristensen, Annika Lindblom, Jolanta Lissowska, Jan Lubinski, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, Dimitrios Mavroudis, William G. Newman, Nadia Obi, Mihalis Panayiotidis, Muhammad U. Rashid, Valerie Rhenius, Matti A. Rookus, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Reijo Sironen, Melissa C. Southey, Maija Suvanto, Rob A. E. M. Tollenaar, Ian Tomlinson, Therese Truong, Lizet E. van der Kolk, Elke M. van Veen, Barbara Wappenschmidt, Xiaohong R. Yang, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Douglas F. Easton, Michael Lush, Kyriaki Michailidou, Paul D. P. Pharoah, Qin Wang, Muriel A. Adank, Marjanka K. Schmidt, Irene L. Andrulis, Jenny Chang-Claude, Heli Nevanlinna, Georgia Chenevix-Trench, D. Gareth Evans, Roger L. Milne, Paolo Radice, Paolo Peterlongo

Summary: Evidence from the BRIDGES study suggests that germline protein truncating variants (PTVs) in FANCM are associated with increased risk of ER-negative and triple-negative breast cancer (TNBC), particularly for those with a family history. This study further investigates the association between FANCM missense variants (MVs) and breast cancer risk using the BRIDGES study, analyzing a total of 689 MVs. The results indicate that FANCM MVs may be low/moderate risk factors for ER-negative and TNBC subtypes of breast cancer.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Clinical Neurology

Increased Circulating Chemokines and Macrophage Recruitment in Growing Vestibular Schwannomas

Cathal John Hannan, Daniel Lewis, Claire O'Leary, Mueez Waqar, David Brough, Kevin N. Couper, Douglas P. Dyer, Andy Vail, Calvin Heal, Joshua Macarthur, Christopher Cooper, Charlotte Hammerbeck-Ward, D. Gareth Evans, Scott A. Rutherford, Simon K. Lloyd, Simon Richard Mackenzie Freeman, David John Coope, Andrew T. King, Omar Nathan Pathmanaban

Summary: There is evidence that macrophage infiltration in the tumor microenvironment promotes the growth of vestibular schwannoma (VS). The efficacy of bevacizumab in NF2-associated VS demonstrates the value of targeting the microvascular tumor microenvironment, and tumor-associated macrophages (TAMs) may represent another druggable target.

NEUROSURGERY (2023)

Article Oncology

What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study

Lorna McWilliams, Helen Ruane, Fiona Ulph, Victoria G. Woof, Fiona Harrison, D. Gareth Evans, David P. French

Summary: Risk-stratified breast screening is being considered for national breast screening programmes. This study aimed to explore the psychological impact of undergoing risk-stratified screening within England's NHS Breast Screening Programme. The findings suggest that risk-stratified breast screening is generally accepted but issues related to risk communication and access to care pathways need to be considered for implementation.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)

D. Gareth Evans, Lorna McWilliams, Susan Astley, Adam R. Brentnall, Jack Cuzick, Richard Dobrashian, Stephen W. Duffy, Louise S. Gorman, Elaine F. Harkness, Fiona Harrison, Michelle Harvie, Andrew Jerrison, Matthew Machin, Anthony J. Maxwell, Sacha J. Howell, Stuart J. Wright, Katherine Payne, Nadeem Qureshi, Helen Ruane, Jake Southworth, Lynne Fox, Sarah Bowers, Gillian Hutchinson, Emma Thorpe, Fiona Ulph, Victoria Woof, Anthony Howell, David P. French

Summary: The study developed BC-Predict, a risk assessment tool that collects standard risk factor information, mammographic density, and Polygenic Risk Score (PRS) to predict the risk of breast cancer. The results showed that inviting women at high and moderate risk for additional screening and preventive measures can increase the uptake of preventive medication.

BRITISH JOURNAL OF CANCER (2023)

Article Genetics & Heredity

Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer

D. Gareth Evans, George J. Burghel, Helene Schlecht, Elaine F. Harkness, Ashu Gandhi, Sacha J. Howell, Anthony Howell, Claire Forde, Fiona Lalloo, William G. Newman, Miriam Jane Smith, Emma Roisin Woodward

Summary: This study aimed to investigate the frequency of germline pathogenic variants (PVs) in women with bilateral breast cancer. BRCA1/2 and CHEK2 c.1100delC molecular analysis were conducted in 764 samples, and a multigene panel was performed in 156 samples. The detection rates of PVs were assessed according to age at first primary, Manchester Score, and breast pathology. The results showed high rates of detection of BRCA1 and BRCA2 PVs in triple negative and grade 3 ER+HER2- first primary diagnoses, respectively. The study also found that the ER status of the first primary strongly predicted the ER status of the second contralateral tumor in BRCA1/2 patients.

JOURNAL OF MEDICAL GENETICS (2023)

Article Ophthalmology

Feasibility and repeatability of ocular biometry measured with IOLMaster 700 in a large population-based study

Ralph Michael, Kerstin Wirkner, Christoph Engel, Markus Loeffler, Toralf Kirsten, Franziska G. Rauscher

Summary: The feasibility and repeatability of IOLMaster 700 biometry measurements in an adult population were evaluated in this study. The study found that the device could successfully measure axial length, central corneal thickness, anterior chamber depth, lens thickness, and keratometry for the majority of eyes. The use of built-in quality indicators significantly improved measurement variability. Repeatability measurements indicated that clinically meaningful changes can be reliably detected with this instrument.

OPHTHALMIC AND PHYSIOLOGICAL OPTICS (2023)

Article Multidisciplinary Sciences

Deficiency of the minor spliceosome component U4atac snRNA secondarily results in ciliary defects in human and zebrafish

Deepak Khatri, Audrey Putoux, Audric Cologne, Sophie Kaltenbach, Alicia Besson, Eloise Bertiaux, Justine Guguin, Adele Fendler, Marie A. Dupont, Clara Benoit-Pilven, Leila Qebibo, Samira Ahmed-Elie, Severine Audebert-Bellanger, Pierre Blanc, Thomas Rambaud, Martin Castelle, Gaelle Cornen, Sarah Grotto, Agnes Guet, Laurent Guibaud, Caroline Michot, Sylvie Odent, Lyse Ruaud, Elise Sacaze, Virginie Hamel, Remy Bordonne, Anne -Louise Leutenegger, Patrick Edery, Lydie Burglen, Tania Attie-Bitach, Sylvie Mazoyer, Marion Delous

Summary: In the human genome, 750 genes contain one intron excised by the minor spliceosome. Mutations in the noncoding gene RNU4ATAC have been found in several syndromes. This study reveals bi-allelic RNU4ATAC mutations in patients with Joubert syndrome, expanding the spectrum of RNU4ATAC-associated disorders and suggesting ciliary dysfunction as a downstream mechanism of minor splicing defects.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Urology & Nephrology

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

Fei Chen, Ravi K. Madduri, Alex A. Rodriguez, Burcu F. Darst, Alisha Chou, Xin Sheng, Anqi Wang, Jiayi Shen, Edward J. Saunders, Suhn K. Rhie, Jeannette T. f Bensen, Sue A. Ingles, Rick A. Kittles, Sara S. Strom, Benjamin A. Rybicki, Barbara Nemesure, William B. Isaacs, Janet L. Stanford, Wei Zheng, Maureen Sanderson, Esther M. John, Jong Y. Park, Jianfeng Xu, Ying Wang, Sonja I. Berndt, Chad D. Huff, Edward D. Yeboah, Yao Tettey, Joseph Lachance, Wei Tang, Christopher T. Rentsch, Kelly Cho, Benjamin H. Mcmahon, Richard B. Biritwum, Andrew A. Adjei, Evelyn Tay, Ann Truelove, Shelley Niwa, Thomas A. Sellers, Kosj Yamoah, Adam B. Murphy, Dana C. Crawford, Alpa V. Patel, William S. Bush, Melinda C. Aldrich, Olivier Cussenot, Gyorgy Petrovics, Jennifer Cullen, Christine M. Neslund-Dudas, Mariana C. Stern, Zsofia Kote-Jarai, Koveela Govindasami, Michael B. Cook, Anand P. Chokkalingam, Ann W. Hsing, Phyllis J. Goodman, Thomas J. Hoffmann, Bettina F. Drake, Jennifer J. Hu, Jacob M. Keaton, Jacklyn N. Hellwege, Peter E. Clark, Mohamed Jalloh, Serigne M. Gueye, Lamine Niang, Olufemi Ogunbiyi, Michael O. Idowu, Olufemi Popoola, Akindele O. Adebiyi, Oseremen I. Aisuodionoe-Shadrach, Hafees O. Ajibola, Mustapha A. Jamda, Olabode P. Oluwole, Maxwell Nwegbu, Ben Adusei, Sunny Mante, Afua Darkwa-Abrahams, James E. Mensah, Halimatou Diop, Stephen K. Van Den Eeden, Pascal Blanchet, Jay H. Fowke, Graham Casey, Anselm J. Hennis, Alexander Lubwama, Ian M. Thompson, Robin Leach, Douglas F. Easton, Michael H. Preuss, Ruth J. Loos, Susan M. Gundell, Peggy Wan, James L. Mohler, Elizabeth T. Fontham, Gary J. Smith, Jack A. Taylor, Shiv Srivastava, Rosaline A. Eeles, John D. Carpten, Adam S. Kibel, Luc Multigner, Marie-Elise Parent, Florence Menegaux, Geraldine Cancel-Tassin, Eric A. Klein, Caroline Andrews, Timothy R. Rebbeck, Laurent Brureau, Stefan Ambs, Todd L. Edwards, Stephen Watya, Stephen J. Chanock, John S. Witte, William J. Blot, J. Michael Gaziano, Amy C. Justice, David Conti, Christopher A. Haiman

Summary: In this study, a large-scale genetic analysis was conducted in men of African ancestry, leading to the discovery of nine novel risk variants for prostate cancer (PCa). Furthermore, a multiancestry polygenic risk score was developed to effectively stratify PCa risk and differentiate the risk of aggressive and nonaggressive disease.

EUROPEAN UROLOGY (2023)

Article Oncology

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation

Mark van Barele, Delal Akdeniz, Bernadette A. M. Heemskerk-Gerritsen, Margreet G. E. M. Genepso, Nadine Andrieu, Catherine Nogues, Encarnacion B. Hebon, Christi J. van Asperen, Marijke Wevers, Margreet G. E. M. Ausems, Geertruida H. de Bock, Charlotte J. Dommering, Encarnacion B. Gomez-Garcia, Flora E. van Leeuwen, Thea M. Mooij, Carole Embrace, Douglas F. Easton, Antonis C. Antoniou, D. Gareth Evans, Louise Izatt, Marc Tischkowitz, Debra Frost, Carole Brewer, Edit Olah, Jacques Simard, Christian F. Singer, Mads Thomassen, Karin Kast, Kerstin Rhiem, Christoph Engel, Miguel de la Hoya, Lenka Foretova, Anna Jakubowska, Agnes Jager, Margriet G. A. Sattler, Marjanka K. Schmidt, Maartje J. Hooning

Summary: This study found that adjuvant radiation therapy for primary breast cancer may increase the risk of contralateral breast cancer in patients with gBRCA1/2 pathogenic variant. This is especially concerning for young patients who already have a high risk of contralateral breast cancer and potentially increased genetic susceptibility to radiation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

Anna Morra, Maartje A. C. Schreurs, Irene L. Andrulis, Hoda Anton-Culver, Annelie Augustinsson, Matthias W. Beckmann, Sabine Behrens, Stig E. Bojesen, Manjeet K. Bolla, Hiltrud Brauch, Annegien Broeks, Saundra S. Buys, Nicola J. Camp, Jose E. Castelao, Melissa H. Cessna, Jenny Chang-Claude, Wendy K. Chung, Sarah Colonna, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Joe Dennis, Peter Devilee, Thilo Doerk, Alison M. Dunning, Miriam Dwek, Douglas F. Easton, Diana M. Eccles, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Tanja N. Fehm, Jonine D. Figueroa, Henrik Flyger, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Jeanine A. Genkinger, Felix Grassmann, Melanie Guendert, Eric Hahnen, Christopher Haiman, Ute Hamann, Patricia A. Harrington, Jaana M. Hartikainen, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, Anna Jakubowska, Wolfgang Janni, Helena Jernstroem, Esther M. John, Nichola Johnson, Michael E. Jones, Vessela N. Kristensen, Allison Kurian, Diether Lambrechts, Loic Le Marchand, Annika Lindblom, Jan Lubinski, Michael P. Lux, Arto Mannermaa, Dimitrios Mavroudis, Anna Marie Mulligan, Taru A. Muranen, Heli Nevanlinna, Ines Nevelsteen, Patrick Neven, William G. Newman, Nadia Obi, Kenneth Offit, Andrew F. Olshan, Tjoung-Won Park-Simon, Alpa Patel, Paolo Peterlongo, Kelly-Anne Phillips, Dijana Plaseska-Karanfilska, Eric C. Polley, Nadege Presneau, Katri Pylkas, Brigitte Rack, Paolo Radice, Muhammad U. Rashid, Valerie Rhenius, Mark Robson, Atocha Romero, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Sabine Schuetze, Christopher Scott, Mitul T. Shah, Snezhana Smichkoska, Melissa C. Southey, William J. Tapper, Lauren R. Teras, Rob A. E. M. Tollenaar, Katarzyna Tomczyk, Ian Tomlinson, Melissa Troester, Celine Vachon, Elke van Veen, Qin Wang, Camilla Wendt, Hans Wildiers, Robert A. Winqvist, Argyrios Ziogas, Per Hall, Paul D. P. Pharoah, Muriel Adank, Antoinette Hollestelle, Marjanka K. Schmidt, Maartje Hooning

Summary: Breast cancer patients with the CHEK2 c.1100delC variant have an increased risk of contralateral breast cancer and worse survival. Systemic therapy is associated with reduced contralateral breast cancer risk, regardless of CHEK2 c.1100delC status. Patients with the CHEK2 c.1100delC variant have shorter survival, which is not fully explained by their contralateral breast cancer risk.

CANCER MEDICINE (2023)

Article Oncology

Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression

D. Gareth Evans, Dorothy Halliday, Rupert Obholzer, Shazia Afridi, Claire Forde, Scott A. Rutherford, Charlotte Hammerbeck-Ward, Simon K. Lloyd, Simon M. Freeman, Omar N. Pathmanaban, Owen M. Thomas, Roger D. Laitt, Stavros Stivaros, John-Paul Kilday, Grace Vassallo, Catherine McBain, Timothy Lavin, Chay Paterson, Gillian Whitfield, Martin G. McCabe, Patrick R. Axon, Jane Halliday, Samuel Mackeith, Allyson Parry, Elaine F. Harkness, Juliette Buttimore, Andrew T. King

Summary: The use of radiation treatment for benign tumors in NF2-related schwannomatosis patients is associated with an increased risk of subsequent malignancy/malignant progression. Compared to other treatment methods, radiation treatment is more likely to lead to the development of CNS malignancies. Therefore, the use of radiation treatment for benign tumors in NF2 patients should be avoided, and patients should be given thorough explanations.

NEURO-ONCOLOGY ADVANCES (2023)

Review Oncology

Dominantly inherited micro-satellite instable cancer - the four Lynch syndromes - an EHTG, PLSD position statement

Pal Moller, Toni T. Seppala, Aysel Ahadova, Emma J. Crosbie, Elke Holinski-Feder, Rodney Scott, Saskia Haupt, Gabriela Moeslein, Ingrid Winship, Sanne W. Bajwa-ten Broeke, Kelly E. Kohut, Neil Ryan, Peter Bauerfeind, Laura E. Thomas, D. Gareth Evans, Stefan Aretz, Rolf H. Sijmons, Elizabeth Half, Karl Heinimann, Karoline Horisberger, Kevin Monahan, Christoph Engel, Giulia Martina Cavestro, Robert Fruscio, Naim Abu-Freha, Levi Zohar, Luigi Laghi, Lucio Bertario, Bernardo Bonanni, Maria Grazia Tibiletti, Leonardo S. Lino-Silva, Carlos Vaccaro, Adriana Della Valle, Benedito Mauro Rossi, Leandro Apolinario da Silva, Ivana Lucia de Oliveira Nascimento, Norma Teresa Rossi, Tadeusz Debniak, Jukka-Pekka Mecklin, Inge Bernstein, Annika Lindblom, Lone Sunde, Sigve Nakken, Vincent Heuveline, John Burn, Eivind Hovig, Matthias Kloor, Julian R. Sampson, Mev Dominguez-Valentin, Prospective Lynch Syndrome Database, European Hereditary Tumour Grp

Summary: The recognition of hereditary micro-satellite instable (MSI) cancers caused by pathogenic variants in mismatch repair (MMR) genes has changed our understanding of carcinogenesis. The four Lynch syndromes, each caused by loss of function variants in MMR genes, are characterized by different levels and types of cancer. In Lynch syndromes, carcinogenesis follows a linear process with a dynamic balance between MSI production and the host's immune system. Colonoscopy surveillance, aspirin prevention, and immunotherapy are important advancements in preventing and treating hereditary MSI cancer.

HEREDITARY CANCER IN CLINICAL PRACTICE (2023)

暂无数据